Sanofi: latest news - GoINPHARMA
Tuesday, 16 October 2018 - 19:50

Sanofi

Good Phase III results for Regeneron and Sanofi’s Dupixent

Regeneron Pharmaceuticals and Sanofi have announced at the  27th European Academy of Dermatology and Venereology (EADV) Congress, in Paris, positive results from a Phase III clinical trial assessing Dupixent (dupilumab) on adolescents with atopic dermatitis. The study was conducted on…

Sanofi to shut down immediately Mourenx factory over excessive toxic waste

An inspection by French competent authorities at Sanofi’s Mourenx chemical factory in the Pyrenees revealed that toxic waste emissions of some molecules are exceeding the authorized levels  by 90,000. In particular, France Nature Environnement denounced today astronomical quantities of pollutants…

Sanofi transfers infectious disease unit to Evotec

Germany-based Evotec today has announced it has signed an agreement with Sanofi to integrate Sanofi’s infectious disease portfolio, together with 100 employees and €60m, into its organization. The terms of the agreement were already disclosed by the groups in March,…

Sanofi to sell Recipharm CMO business in UK for GBP54m

France-based Sanofi has sold to Sweden-based Recipharm AB its CMO business in UK, including the Manchester, UK-based Holmes Chapel manufacturing site, focusing on products for the respiratory drug market. The division yielded a revenue of  GBP51m over the last 12…

Sanofi disappoints market with poor quarter results

Sanofi pharmaceutical group has disappointed its shareholders and investors with Q1 results below expectations, and its shares have lost 1.7% (Paris). The France-based group delivered revenues of €7.9bn over the first three months of the year, with €1bn net income,…

Sanofi sells 12 drugs to Cooper-Vemedia for €158m

The Belgian daily der Standard has reported that Sanofi has sold 12 brands to Cooper-Vemedia for €158m. The sale is part of Sanofi’s strategy to simplify its product portfolio and fund its recent acquisitions. Cooper-Vemedia belongs to private equity Charterhouse…

Advent offers €1.919bn for Sanofi’s Zentiva

Private equity Advent International has announced today in a press release that it is in exclusive talks with Sanofi to acquire Zentiva, the French company’s arm that markets generics all over Europe. Advent has offered Sanofi €1.919bn. Advent International, which…

Sanofi invests €350m on new vaccine production plant

France-based Sanofi has confirmed this week a significant €350m (CA$500m) investment to build a vaccine production plant in its plant in Toronto, Canada. The new investment makes the Canadian site one of the main plants of the group, with over…

Advent Capital now about to acquire Sanofi’s Zentiva ($2bn)

Advent International is reportedly about to acquire Zentiva, Sanofi’s European arm marketing generics. Advent has beaten its competitor, the investor BC Partners, the Financial Times has reported. Private equities Blackstone and Nordic Capital have already pulled out from the race…

Sanofi seeks to restore leadership in diabetes treatments

Sanofi is trying to restore its leading position in diabetes treatments, like at the time when its insulin Lantus was among blockbusters. The France-based group is now largely focusing on sotagliflozin, which acts as a SGLT-1 and SGLT-2 inhibitor and…

M&A of Consumer Health units at a stalemate

The market provides with a wide range of opportunities those companies that want to enhance their Consumer Health portfolio through acquisitions. Assets are currently on sale by Germany-based Merck KGaA, intending to dismiss its Consumer Health arm for €4bn, and…

Sanofi about to sell know-how and R&D center to Evotec for €60m

Germany-based Evotec and its French competitor Sanofi yesterday announced they are in talks for an agreement to license to Evotec the know-how developed by Sanofi in infectious diseases. Sanofi’s package does not include any product currently marketed, while it does…

Sanofi Genzyme announces 130 staff cuts

Sanofi Genzyme has announced today it will dismiss 130 employees at Allston Landing plant in Boston. The decision reflects the need to cut prices and simplify production processes. Sanofi acquired the site in 2011, after acquiring Genzyme. Sanofi currently has…

Diabetes business increasingly struggling

In the past, the diabetes business used to deliver excellent margins and considerable growth rate, which encouraged many companies to join it and launch new products. Increased competition and pressure on prices by authorities have resulted in the current global-scale…

Battle over Ablynx begins

Bloomberg has reported that Denmark-based Novo Nordisk is preparing a new bid to acquire Belgium-based biotech Ablynx. The offer would significantly improve the previous one-€2.6bn-and could be submitted as early as next week. Ablynx has tried to enter into talks…

Why big pharma companies always create new spinoffs

The recent acquisitions in the pharma sector (Sanofi, Celgene, Biogen) have confirmed that the strategy adopted by many groups–i.e. spinning off part of their assets and divesting them–is the best way to grant shareholders a rich financial return. The most…

Confirmed: Sanofi buys Bioverativ for $11.6bn

Sanofi has announced today in the morning, before trading started, that it has acquired US-based Bioverativ for $11.6bn in cash, corresponding to $105 per share, that is a 64% premium over Friday night’s closing price. The deal enhances Sanofi’s hemophilia…

Sanofi about to acquire Bioverativ for $11.5bn (63% premium)

The Wall Street Journal yesterday reported, late at night, that France-based Sanofi is about to acquire Bioverativ Inc. for approximately $11.5bn, that is $105 per share, which would correspond to a 63% premium over last Friday’s closing price. Investors in…

Battle over Sanofi’s Zentiva ($2bn) begins

The Economic Times India yesterday reported that India-based Aurobindo, Zydus Cadila, Torrent Pharma and Intas are targeting Sanofi’s European generics business, which is managed by Czech subsidiary Zentiva. Zentiva is worth at least $1.5-$2.0bn, according to analysts, and has drawn…

Sanofi’s Toujeo bests Tresiba in clinical trial with 929 patients

Sanofi has announced today that its insulin Toujeo has met the primary endpoint vs Novo Nordisk’s insulin Tresiba (degludec) in the Bright clinical trial.  Bright has been conducted on 829 patients with type II diabetes and its complete results will…